#USA #Cancer Treatment #Avondale #CQ Medical #.decimal

CQ Medical Expands Horizons in Cancer Treatment with .decimal Acquisition

CQ Medical, recognized as a global leader in patient radiotherapy positioning and healthcare innovations, recently announced its acquisition of .decimal, a specialized manufacturer known for its advanced cancer treatment equipment and patient-specific beam shaping devices. This acquisition is expected to significantly enhance CQ Medical's capabilities in offering tailored cancer therapies and improve overall patient care.

Overview of .decimal and Its Impact

Founded over 40 years ago, .decimal has established a reputation in the radiotherapy community for its quick turnaround times, usually producing and shipping customized treatment devices within just one to two days of receiving an order. The company has successfully supplied over 500,000 patient-specific treatment devices to more than 900 cancer centers across the United States, showcasing its commitment to patient-centric care.

By acquiring .decimal, CQ Medical not only broadens its product range but also strengthens its position as a comprehensive solutions provider in the field of cancer treatment. This merger means CQ Medical can now boast enhanced manufacturing capabilities, which will be pivotal in driving future innovations in patient care.

CQ Medical's Origins and Expertise

CQ Medical was established in 2022 following the merger of two prominent entities, CIVCO Radiotherapy and Qfix, combining decades of experience in the essential radiation therapy sector. The company specializes in a variety of clinical applications, including:

• - Precision stereotactic treatments and proton therapy
• - Implantable fiducial markers for image-guided radiotherapy
• - Customizable thermoplastic products for patient immobilization
• - Systems for patient transfer during radiotherapy and interventional cardiology procedures

These offerings already demonstrate CQ Medical's comprehensive approach to cancer treatment, making the addition of .decimal's rapid production capabilities even more valuable.

Commentary from Leadership

Michael Galbus, the CEO of CQ Medical, expressed enthusiasm about the acquisition, stating, “We are excited to welcome the highly talented .decimal team to CQ Medical. Their commitment to quality and patient care aligns closely with our mission to improve care and outcomes through a passion for innovation.”

This sentiment is echoed by .decimal's CEO, Richard Sweat, who underscores the perfect alignment between the two companies’ goals, emphasizing that this partnership will amplify the positive impact they have on clinicians and patients worldwide.

Future Directions Post-Acquisition

Following the acquisition, .decimal will continue to operate out of its facility in Sanford, Florida, ensuring that the quality and support it’s known for remains uninterrupted. CQ Medical is committed to working closely with existing .decimal customers to guarantee a seamless transition, maintaining the high standards both organizations uphold.

As the healthcare landscape evolves, partnerships like the one between CQ Medical and .decimal demonstrate a crucial trend in the industry: the necessity for innovation and personalized care. With this merger, both companies are well-positioned to lead advancements in radiotherapy and enhance collaborations with clinical and research partners.

Conclusion

CQ Medical's acquisition of .decimal is a strategic move that promises to enhance patient-specific cancer treatment solutions significantly. With a shared vision for innovation and quality care, this partnership is poised to reshape the landscape of cancer therapy, making strides toward improving patient outcomes across the globe. As CQ Medical continues to push the boundaries of healthcare technology, the future looks promising for both patients and medical professionals alike.